Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
NCT03332589 · Spirita Oncology, LLC · PHASE1 · terminated · last registry update 2022-05-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Single center study: Principal Investigator left institution.” | – | Registry record, Spirita Oncology, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAP2K1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-19Results posted on the registry: Novartis Pharmaceuticals, Dabrafenib + trametinib (NCT02684058)
- 2023-04-11Results posted on the registry: National Cancer Institute (NCI), AZD6244 + MK-2206 (NCT01306045)
- 2023-03-14Phase 3 first posted: Cancer Research UK, Vemurafenib + Cobimetinib (NCT05768178)
- 2023-02-10Phase 3 first posted: Cancer Research UK, Alectinib + Atezolizumab (NCT05722886)
- 2022-12-29Results posted on the registry: Academic and Community Cancer Research United, Binimetinib + Palbociclib (NCT03981614)
- 2022-12-28Results posted on the registry: National Cancer Institute (NCI), Trametinib (NCT02152995)
- 2022-12-23Results posted on the registry: University of Colorado, Denver, Pembrolizumab + Bevacizumab (NCT03475004)
- 2022-12-13Results posted on the registry: National Cancer Institute (NCI), Selumetinib + Selumetinib Sulfate (NCT03213691)
- 2022-11-14Phase 3 first posted: UNICANCER, Futibatinib + Ivosidenib (NCT05615818)
- 2022-08-30Results posted on the registry: Pierre Fabre Medicament, encorafenib + Binimetinib (NCT03693170)
- 2022-03-08Phase 3 first posted: Pierre Fabre Medicament, Encorafenib and Binimetinib + Placebo to match Encorafenib ; Placebo to match Binimetinib (NCT05270044)
- 2022-02-08Results posted on the registry: Memorial Sloan Kettering Cancer Center, Trametinib + Erlotinib (NCT03076164)
- 2021-08-17Results posted on the registry: National Cancer Institute (NCI), Binimetinib (NCT04439344)
- 2021-08-03Results posted on the registry: Academic and Community Cancer Research United, Selumetinib (NCT02393690)
- 2021-07-12Results posted on the registry: Pfizer, LGX818 + MEK162 (NCT01909453)
- 2021-07-02Phase 3 first posted: The Netherlands Cancer Institute, Neoadjuvant ipilimumab + nivolumab + Adjuvant nivolumab (NCT04949113)
- 2021-06-25Phase 3 first posted: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT04940052)
- 2021-06-22Results posted on the registry: Canadian Cancer Trials Group, Selumetinib + Pemetrexed (NCT02337530)
- 2021-06-14Phase 3 first posted: AstraZeneca, Selumetinib (NCT04924608)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision